Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GSK reports second quarter earnings

GlaxoSmithKline (LSE:GSK; GSK) reported second quarter EPS of 23.9p, up 2p (9%) from the same period last year. The

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE